KYORIN Pharmaceutical Co.,Ltd. (JP:4569)
:4569
Want to see JP:4569 full AI Analyst Report?
Top Page
KYORIN Pharmaceutical Co.,Ltd.
(4569)
Select Model
Select Model
Rating:54Neutral
Price Target:
¥1,448.00
▼(-5.79% Downside)
Action:Reiterated
Date:05/16/26
Overall score reflects solid balance-sheet strength but meaningful recent profitability compression and a historically volatile free-cash-flow profile. Technicals are weak with the stock trading below major moving averages and negative MACD, while valuation is mixed—an attractive ~4% dividend yield is offset by a relatively high ~27x P/E.
Positive Factors
Conservative balance sheet
Low leverage (debt-to-equity ~0.17) and steadily growing equity provide financial flexibility to fund R&D, withstand NHI pricing shifts, and support licensing or M&A activity. A conservative capital structure reduces refinancing risk and underpins multi‑quarter resilience for a specialty pharma business.
Negative Factors
Margin compression
Sharp declines in gross and net margins materially reduce internal funding for R&D and commercialization. Persistent margin pressure would force either cost-cutting, reduced investment, or pricing reliance under Japan's reimbursement system, weakening sustainable profitability over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage (debt-to-equity ~0.17) and steadily growing equity provide financial flexibility to fund R&D, withstand NHI pricing shifts, and support licensing or M&A activity. A conservative capital structure reduces refinancing risk and underpins multi‑quarter resilience for a specialty pharma business.
Read all positive factors
KYORIN Pharmaceutical Co.,Ltd. (4569) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥71.27B
Dividend Yield3.36%
Average Volume (3M)127.03K
Price to Earnings (P/E)27.4
Beta (1Y)0.54
Revenue Growth-2.94%
EPS Growth-62.05%
CountryJP
Employees2,042
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)179.30
Shares Outstanding59,945,640
10 Day Avg. Volume147,840
30 Day Avg. Volume127,030
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)0.66
Price to Sales (P/S)0.75
P/FCF Ratio37.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)77.6
Revenue Forecast (FY)¥125.58B
KYORIN Pharmaceutical Co.,Ltd. Business Overview & Revenue Model
Company Description
KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent;...
How the Company Makes Money
KYORIN Pharmaceutical makes money primarily by selling prescription pharmaceuticals. Its core revenue stream is product sales to wholesalers and medical providers, driven by demand for its branded prescription drugs in its focus therapeutic areas ...
KYORIN Pharmaceutical Co.,Ltd. Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
78
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 131.90B | 126.26B | 130.09B | 119.53B | 113.27B | 105.53B |
| Gross Profit | 60.43B | 51.61B | 59.51B | 51.62B | 50.16B | 49.44B |
| EBITDA | 18.34B | 8.22B | 17.15B | 10.52B | 8.96B | 8.72B |
| Net Income | 10.30B | 3.45B | 9.09B | 5.47B | 4.72B | 3.93B |
Balance Sheet | ||||||
| Total Assets | 190.57B | 195.46B | 193.62B | 177.63B | 176.04B | 171.92B |
| Cash, Cash Equivalents and Short-Term Investments | 16.62B | 15.08B | 16.51B | 13.98B | 19.39B | 27.49B |
| Total Debt | 26.48B | 23.79B | 28.44B | 20.95B | 21.28B | 21.62B |
| Total Liabilities | 54.41B | 53.02B | 57.33B | 46.89B | 50.58B | 47.41B |
| Stockholders Equity | 136.15B | 142.43B | 136.28B | 130.74B | 125.46B | 124.51B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 2.52B | -2.19B | -4.23B | -4.32B | 3.90B |
| Operating Cash Flow | 0.00 | 6.38B | 3.51B | 1.55B | 2.01B | 6.35B |
| Investing Cash Flow | 0.00 | -1.64B | -6.32B | -3.19B | -6.28B | -2.56B |
| Financing Cash Flow | 0.00 | -7.96B | 3.95B | -3.35B | -3.36B | -4.11B |
KYORIN Pharmaceutical Co.,Ltd. Technical Analysis
Negative
1537.00
Price Trends
1576.93
Negative
1584.71
Negative
1517.93
Negative
Market Momentum
-69.38
Positive
20.40
Positive
7.18
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4569, the sentiment is Negative. The current price of 1537 is above the 20-day moving average (MA) of 1481.05, below the 50-day MA of 1576.93, and above the 200-day MA of 1517.93, indicating a bearish trend. The MACD of -69.38 indicates Positive momentum. The RSI at 20.40 is Positive, neither overbought nor oversold. The STOCH value of 7.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4569.
KYORIN Pharmaceutical Co.,Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | ¥283.49B | 22.21 | ― | 2.12% | 6.58% | -8.74% | |
66 Neutral | ¥124.37B | 19.64 | 4.81% | 2.34% | 11.21% | 39.02% | |
58 Neutral | ¥169.72B | 14.03 | 6.70% | 2.48% | 10.28% | 20.78% | |
54 Neutral | ¥71.27B | 27.41 | ― | 3.36% | -2.94% | -62.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥147.86B | 73.21 | -2.58% | 4.16% | -18.25% | -84.71% | |
48 Neutral | ¥191.44B | 37.55 | 12.02% | 2.14% | 5.44% | -72.35% |
* Healthcare Sector Average
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,301.00
-103.34
-7.36%
JP:4521
Kaken Pharmaceutical Co
4,085.00
495.61
13.81%
JP:4547
Kissei Pharmaceutical Co
4,025.00
268.04
7.13%
JP:4553
Towa Pharmaceutical Co
3,935.00
924.94
30.73%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,540.00
643.67
22.22%
JP:4516
Nippon Shinyaku Co., Ltd.
4,211.00
876.26
26.28%
KYORIN Pharmaceutical Co.,Ltd. Corporate Events
KYORIN Expands Performance-Linked Stock Compensation Plan to Corporate Officers
May 12, 2026
KYORIN Pharmaceutical has approved a partial revision of its performance-linked stock compensation plan, which was originally introduced in 2016 and updated in 2023. The key change is the inclusion of corporate officers under delegation agreements...
KYORIN Pharmaceutical Reshapes Board and Audit Team in June Leadership Overhaul
May 12, 2026
KYORIN Pharmaceutical Co., Ltd. has announced a reshuffle of its governance structure, including new director and auditor appointments effective June 19, 2026, subject to approval at the upcoming Ordinary General Meeting of Shareholders and subseq...
KYORIN Sets Aggressive Investment Plan in New Medium-Term Strategy “Vision 110 – Stage 2 –”
May 12, 2026
KYORIN Pharmaceutical has unveiled its new medium-term business plan, “Vision 110 – Stage 2 –,” covering fiscal years 2026 to 2029 as part of a broader long-term strategy leading up to its 110th anniversary. The plan center...
KYORIN Pharmaceutical Misses Interim Profit Forecasts on Weaker Sales and Higher R&D Costs
May 12, 2026
KYORIN Pharmaceutical reported that its consolidated interim results for the fiscal year ending March 31, 2026 fell short of prior forecasts, with net sales marginally below expectations but profits significantly underperforming. Operating profit,...
KYORIN Pharmaceutical Announces Consolidated Results and Outlook for FY2025
May 12, 2026
KYORIN Pharmaceutical released an outline of its consolidated financial results for the fiscal year ended March 31, 2026, including net sales by product, research and development expenses, capital expenditure and depreciation. The disclosure also ...
Kyorin Pharmaceutical Slashes Profit Outlook and Plans Dividend Cut After Sharp Earnings Decline
May 12, 2026
Kyorin Pharmaceutical reported a 2.9% decline in consolidated net sales to ¥126.3 billion for the year to March 31, 2026, with operating profit plunging 71.6% and profit attributable to owners of parent dropping 62.0%, reflecting significant ...
Kyorin to Transfer Generic Drug Operations to Co-Creation Platform with Daito
Apr 26, 2026
KYORIN Pharmaceutical has signed a memorandum of understanding with Daito Pharmaceutical and co-investors to advance discussions on transferring its generic drug business, excluding authorized generics, to a new entity called Pharmatech Co-creatio...
KYORIN Licenses BIODOL’s Novel Neuropathic Pain Drug for Key Asian Markets
Mar 31, 2026
KYORIN Pharmaceutical has exercised an option with France’s BIODOL Therapeutics to secure exclusive rights to develop, manufacture, and commercialize BDT272, a novel neuropathic pain treatment candidate, in Japan, South Korea, and Taiwan. Th...
KYORIN Secures Exclusive Japan Rights to Promote and Distribute J&J’s SIRTURO
Mar 25, 2026
KYORIN Pharmaceutical has signed an exclusive distribution and promotion agreement in Japan with Johnson Johnson’s Janssen unit for SIRTURO, an oral diarylquinoline antimycobacterial drug already marketed domestically as part of combination...
Kyorin Pharma Overhauls Governance With New Mandate-Based Officer System
Feb 26, 2026
Kyorin Pharmaceutical will introduce a mandate-based corporate officer system from April 1, 2026, alongside its existing employment-based framework. The move is designed to strengthen corporate governance by further separating decision-making and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.